Livzon Pharmaceutical Group Inc. (01513.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	10.7B	12.0B	11.8B	12.4B	12.6B
Cost of Revenue	4.0B	4.1B	4.1B	4.8B	4.5B
Gross Profit	6.7B	7.9B	7.7B	7.7B	8.2B
Operating Expenses
R&D Expense	813.5M	821.0M	1.0B	1.3B	1.4B
SG&A Expense	3.5B	3.3B	3.0B	4.3B	4.5B
General & Admin Expense	(19.7M)	161.6M	195.0M	654.3M	656.9M
Selling & Marketing Expense	1.7B	3.1B	2.8B	3.6B	3.9B
Other Expenses	183.8M	858.8M	882.2M	(344.6M)	(36.9M)
Total Operating Expenses	4.5B	5.0B	4.9B	5.2B	5.9B
Cost and Expenses	8.5B	9.0B	9.0B	10.0B	10.4B
Operating Income (EBIT)	2.2B	2.9B	2.8B	2.4B	2.4B
Non-Operating
Interest Income	206.3M	290.5M	248.0M	368.2M	315.1M
Interest Expense	48.8M	60.1M	88.6M	102.1M	97.5M
Net Interest Income	157.4M	230.3M	155.9M	261.3M	212.1M
Other Non-Op Income/Expense	148.2M	(84.1M)	(38.3M)	(32.4M)	(20.0M)
Non-Operating Income (excl Interest)	92.7M	319.4M	(50.4M)	(69.6M)	(77.5M)
EBT (Pre-Tax Income)	2.4B	2.9B	2.8B	2.4B	2.3B
Income Tax Expense	377.6M	451.0M	501.7M	485.1M	375.0M
Bottom Line
Net Income	1.7B	2.0B	2.1B	2.0B	1.9B
Earnings from Cont. Ops	2.0B	2.4B	2.3B	1.9B	2.0B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	1.7B	2.0B	2.1B	2.0B	1.9B
Per Share
Basic EPS	HK$1.89	HK$2.27	HK$2.24	HK$2.10	HK$2.04
Diluted EPS	HK$1.89	HK$2.27	HK$2.24	HK$2.10	HK$2.04
Revenue Per Share	HK$12.05	HK$13.46	HK$12.84	HK$13.36	HK$13.52
Shares
Basic Shares Outstanding	887.9M	893.1M	920.1M	930.3M	933.9M
Diluted Shares Outstanding	887.9M	893.1M	920.1M	930.6M	936.0M
Profitability Metrics
EBITDA	2.7B	3.1B	3.5B	3.3B	3.1B
D&A	620.0M	539.0M	575.1M	840.3M	652.3M
EBIT	2.3B	2.6B	2.9B	2.5B	2.4B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026